EMA Panel Backs Uplizna for Neuromyelitis Optica

The immunosuppressant inebilizumab is indicated to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin 4 immunoglobulin G seropositive.
International Approvals

Full Story →